Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDCoAT: Caffeine-based Antifibrosis Cream in Breast Cancer Radiation Therapy
NCT03768492Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in radiation-induced fibrosis (RIF), radiation dermatitis and complications of reconstructive procedures comparing Caffeine Based Cream with Placebo (2 arms). Primary endpoint: Standard Toxicity Scoring at 4 years. Started Jun 2020; status: active, not recruiting.
02
Drugs
caffeine
03
Conditions
radiation-induced fibrosis (RIF)radiation dermatitiscomplications of reconstructive procedures
Beyond the preview
Go deeper on NCT03768492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768492.